TY - JOUR
T1 - A new class of β–pyrrolidino-1,2,3-triazole derivatives as β-adrenergic receptor inhibitors
T2 - Synthesis, pharmacological, and docking studies
AU - Easwaramoorthi, Kaliyappan
AU - Rajendran, Jeya A.
AU - Rao, Kella Chennakesava
AU - Balachandran, Chandrasekar
AU - Arun, Yuvaraj
AU - Mahalingam, Sakkarapalayam M.
AU - Arumugam, Natarajan
AU - Almansour, Abdulrahman I.
AU - Kumar, Raju Suresh
AU - Al-Thamili, Dhaifallah M.
AU - Aoki, Shin
N1 - Funding Information:
Acknowledgments: The authors sincerely thank the management of Malladi Drugs & Pharmaceuticals Ltd., Chennai, India for providing the key raw material pyrrolidinynorephedrine and support to this research activity. The authors acknowledge the Deanship of Scientific Research at King Saud University for funding this work through the Research grant RGP-026.
Funding Information:
Funding: This work was funded by the Deanship of Scientific Research at King Saud University for the Research grant RGP-026.
Publisher Copyright:
© 2019 by the authors.
PY - 2019/9/26
Y1 - 2019/9/26
N2 - New 1,4-disubstituted β-pyrrolidino-1,2,3-triazoles were synthesized using a reusable copper-iodide-doped neutral alumina catalyst. Synthesis of diversely substituted triazoles and recyclability of CuI catalyst explains the broad scope of this protocol. The synthesized compounds were screened for their antimicrobial and anticancer properties. Most of the compounds showed significant antimicrobial activities against all the tested microorganisms compared to standard drugs. Furthermore, compounds 5a, 5e, 5g, 5h, 5i, and 5j showed moderate to potent activities against A549 and HepG-2 cells. In addition, compounds 5g and 5h displayed potential cytotoxicity activity against A549 cells with IC50 values of 72 ± 3.21 and 58 ± 2.31 µM, respectively. The molecular docking study revealed that some of the synthesized compounds exhibited comparable binding as co-crystalized ligands with the DNA topoisomerase IV and anaplastic lymphoma kinase receptors.
AB - New 1,4-disubstituted β-pyrrolidino-1,2,3-triazoles were synthesized using a reusable copper-iodide-doped neutral alumina catalyst. Synthesis of diversely substituted triazoles and recyclability of CuI catalyst explains the broad scope of this protocol. The synthesized compounds were screened for their antimicrobial and anticancer properties. Most of the compounds showed significant antimicrobial activities against all the tested microorganisms compared to standard drugs. Furthermore, compounds 5a, 5e, 5g, 5h, 5i, and 5j showed moderate to potent activities against A549 and HepG-2 cells. In addition, compounds 5g and 5h displayed potential cytotoxicity activity against A549 cells with IC50 values of 72 ± 3.21 and 58 ± 2.31 µM, respectively. The molecular docking study revealed that some of the synthesized compounds exhibited comparable binding as co-crystalized ligands with the DNA topoisomerase IV and anaplastic lymphoma kinase receptors.
KW - Anticancer activity
KW - Antimicrobial activity
KW - Docking studies
KW - ß-adrenoceptors
KW - ß–pyrrolidino-1,2,3-triazole
UR - http://www.scopus.com/inward/record.url?scp=85072696333&partnerID=8YFLogxK
U2 - 10.3390/molecules24193501
DO - 10.3390/molecules24193501
M3 - Article
C2 - 31561635
AN - SCOPUS:85072696333
SN - 1420-3049
VL - 24
JO - Molecules
JF - Molecules
IS - 19
M1 - 3501
ER -